Company intelligence / Profile preview

Diorasis Therapeutics

Sandwich, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

In preclinical models including mice and sheep, their lead program DT003 has demonstrated durable and normalizing intraocular pressure (IOP) reduction after a single intracameral injection targeting the trabecular meshwork; toxicology and IND-enabling studies are ongoing with plans for clinical development

Therapeutic areas: Ophthalmology
Modalities: Gene therapyBiologicViral vector (AAV-based gene therapy)
Industry: Biotech

Drug pipeline

1 asset

DT003

Preclinical

Partnerships

Northway Biotech (CDMO; strategic AAV process and manufacturing partnership for DT003 and future programs)

Beyond the preview

Go deeper on Diorasis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diorasis Therapeutics.

Explore the full profile